Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.
| Brand name | VALSARTAN AND HYDROCHLOROTHIAZIDE |
| Generic name | VALSARTAN AND HYDROCHLOROTHIAZIDE |
| Active ingredient(s) | HYDROCHLOROTHIAZIDE, VALSARTAN |
| Distributed by / for | Mylan Pharmaceuticals, Inc., Morgantown, WV 26505, U.S.A |
| NDC | 0378-6325-05 |
| Full product label | Valsartan and Hydrochlorothiazide Tablets, USP, 320 mg/25 mg, (a) 500-count bottle, Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc., Morgantown, WV 26505, U.S.A. NDC 0378-6325-05. |
| Recalling firm | Mylan Pharmaceuticals Inc. |
| Distribution | Product was distributed throughout the United States. |
| Quantity | 5,660 bottles |
| Recall initiated | 2018-11-20 |
| Report date | 2018-12-19 |
| Recall completed | — |
| Recall number | D-0317-2019 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Morgantown WV United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗